Cutaneous Adverse Drug Eruption: Identifiable with Drug Patch Testing?

Completed

• Conditions: Cutaneous drug eruption; Drug patch test

• Registration Number: TCTR20200107003
• Lead Sponsor: one

Brief Summary

We recommend drug patch testing as a safe method to identify the culprit drug in CADRs especially DRESS, MP, and FDE. The positive drug patch test results may depend on the clinical presentation together with drug categories and duration of time to perform patch testing. In HIV patients, the positive test was associated with low CD4 count and co-positive reaction.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-01-07
• Study Completion: 2020-10-05
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 122

Inclusion Criteria

Patient with cutaneous drug eruption including all delayed type drug eruption
1 DRESS
2 AGEP
3 Morbiliform drug rash
4 lichenoid drug eruption
5 fixed drug eruption
6 SJS , TE

Exclusion Criteria

Patient with immunosuppressive agent
Patient with immediated type drug hypersensitivity such as urticaria and anaphylaxia

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
positive drug patch test 48-96 hours drug patch test

Secondary Outcome Measures

Name	Time	Method
safety 48-96 hours drug patch test